Mutational Analysis of the Defective Protease in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis, a Neurodegenerative Lysosomal Storage Disorder  by Sleat, David E. et al.
Am. J. Hum. Genet. 64:1511–1523, 1999
1511
Mutational Analysis of the Defective Protease in Classic Late-Infantile
Neuronal Ceroid Lipofuscinosis, a Neurodegenerative Lysosomal Storage
Disorder
David E. Sleat,1 Rosalie M. Gin,1 Istvan Sohar,1 Krystyna Wisniewski,3,6 Susan Sklower-Brooks,4
Raju K. Pullarkat,5 David N. Palmer,7 Terry J. Lerner,8,9 Rose-Mary Boustany,10 Peter Uldall,11
Aristotle N. Siakotos,12 Robert J. Donnelly,2 and Peter Lobel1
1Center for Advanced Biotechnology and Medicine and Department of Pharmacology, University of Medicine and Dentistry of New Jersey,
Piscataway, and 2Department of Pathology and Lab Medicine, New Jersey Medical School, Molecular Biocore Facility, Newark; Departments
of 3Pathological Neurobiology, 4Human Genetics, and 5Neurochemistry, New York State Institute for Basic Research in Developmental
Disabilities, Staten Island; 6State University of New York Health Science Center at Brooklyn, Brooklyn; 7Animal and Food Sciences Division,
Lincoln University, Canterbury, New Zealand; 8Molecular Neurogenetics Unit, Massachusetts General Hospital, Charlestown, Massachusetts;
9Department of Neurology, Harvard Medical School, Boston; 10Duke University Medical Center, Department of Pediatrics and Neurobiology,
Durham, North Carolina; 11Juliane Marie Centret, Neuropediatric Clinic, Copenhagen; and 12Department of Pathology, Indiana University
School of Medicine, Indianapolis
Summary
The late-infantile form of neuronal ceroid lipofuscinosis
(LINCL) is a progressive and ultimately fatal neurode-
generative disease of childhood. The defective gene in
this hereditary disorder, CLN2, encodes a recently iden-
tified lysosomal pepstatin-insensitive acid protease. To
better understand the molecular pathology of LINCL,
we conducted a genetic survey of CLN2 in 74 LINCL
families. In 14 patients, CLN2 protease activities were
normal and no mutations were identified, suggesting
other forms of NCL. Both pathogenic alleles were iden-
tified in 57 of the other 60 LINCL families studied. In
total, 24 mutations were associated with LINCL, com-
prising six splice-junction mutations, 11 missense mu-
tations, 3 nonsense mutations, 3 small deletions, and 1
single-nucleotide insertion. Two mutations were partic-
ularly common: an intronic GrC transversion in the
invariant AG of a 3′ splice junction, found in 38 of 115
alleles, and a CrT transition in 32 of 115 alleles, which
prematurely terminates translation at amino acid 208 of
563. An ArgrHis substitution was identified, which was
associated with a late age at onset and protracted clinical
phenotype, in a number of other patients originally di-
agnosed with juvenile NCL.
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Introduction
The neuronal ceroid lipofuscinoses (NCLs) are a group
of related hereditary neurodegenerative diseases that pri-
marily affect children (Boustany 1996). All childhood
forms are fatal and have similar clinical profiles, includ-
ing epileptic seizures, loss of vision, ataxia and loss of
motor coordination, and deterioration of mental capa-
bilities. At the ultrastructural level, NCLs are charac-
terized by the accumulation of an autofluorescent ma-
terial, termed “ceroid-lipofuscin,” in lysosome-like
storage bodies in most cell types of patients.
Several NCLs have been classified, with distinct ge-
netic bases. Infantile NCL (INCL; MIM 256730) is
caused by defects in the gene CLN1 (Vesa et al. 1995),
which encodes a lysosomal enzyme, palmitoyl protein
thioesterase (Camp and Hofmann 1993). The most com-
mon NCLs to occur in the United States are the juvenile
(JNCL; MIM 204200) and classic late-infantile (LINCL;
MIM 204500) forms. In LINCL, the defective gene,
CLN2, encodes a recently identified lysosomal protease
(Sleat et al. 1997). In JNCL, the defective gene, CLN3
(The International Batten Disease Consortium 1995), is
a transmembrane protein that is probably lysosomal
(Jarvela et al. 1998). The normal function of the human
CLN3 protein is not known, although there is evidence
that a yeast homologue is involved in vacuolar pH ho-
meostasis (Pearce and Sherman 1998). The defective
gene,CLN4, in a rare adult form ofNCL (MIM204300)
remains to be identified. There are also at least two var-
iant forms of LINCL. In the Finnish-variant LINCL
(MIM 256731), the defective gene, CLN5, has been
identified (Savukoski et al. 1998) and is a putative trans-
membrane protein of currently unknown function. In
another variant, the defective gene, CLN6, (MIM
Table 1
CLN2 Mutations Associated with LINCL
Family
Source
(Identifier)a
Sample
Type Ethnicity
Age at
Onset
(years)
Lifespan
(years) EM
Presenting
Symptom
CLN2
Proteaseb Allele 1 Allele 2
1 1 (IGF032/85) FB Italian # Italian 3.0 CV ES Deficient 1917CrT (Gln66Stop) 1917CrT (Gln66Stop)
2 2 (GUS15820) LB Spanish-French-English-Irish-
American Indian
3.0 11.5 CV ES Deficient 1946ArG (SJ) 3556GrC (SJ)
3 3 (KEW1) Brain Irish-American Indian-German 3.0 10.2 CV; G ES; VD; CD Deficient 1950GrA (Gly77Arg) 3556GrC (SJ)
4 4 (CABM006) DNA, blood Romany # Romany 2.2 14.8 FP ES Deficient 3004ArG (Gln100Arg)/
5171GrA (Gly389Glu)
3004ArG (Gln100Arg)/
5171GrA (Gly389Glu)
5 1 (IGF087/79) FB Romany # Romany 3.0 CV ES Deficient 3004ArG (Gln100Arg)/
5171GrA (Gly389Glu)
3004ArG (Gln100Arg)/
5171GrA (Gly389Glu)
6 5 (BD00224) LB German-Bohemian #
German-Bohemian
3.0 7.8 CV CD Deficient 3081-3091del 3670CrT (Arg208Stop)
7 13 (2740) Brain Deficient 3081-3091del 3670CrT (Arg208Stop)
8 6 (CABM011) FB Mexican # Mexican 3.0 16.0 CV ES Deficient 3084CrT (Arg127Stop) 3670CrT (Arg208Stop)
9 3 (C10516);
2
(GUS-
24180)
DNA
LB
English-Scottish # English-Scottish 3.5 18.7 CV; FP ES; CD Deficient 3556GrA (SJ) 3556GrC (SJ)
10 7 (DNP1) Brain English # Dutch-English 3.0 7.8 CV ES Deficient 3556GrA (SJ) 3556GrC (SJ)
11 2 (GUS26235);
3 (C11488)
LB
DNA
German # English 3.5 16.5 CV VD Deficient 3556GrA (SJ) 5271GrC (Gln422His)
12 5 (BD00173) LB German # German-English 3.0 8.5 CV ES Deficient 3556GrC (SJ) 3556GrC (SJ)
13 3 (C10557) DNA English # English-Irish 3.0 18.5 CV ES; CD ND 3556GrC (SJ) 3556GrC (SJ)
14 3 (C8878);
5(BD00379)
DNA LB Swedish-English-Irish# Scottish-
Irish-Norwegian
2.5 110.0 CV ES ND 3556GrC (SJ) 3556GrC (SJ)
15 8 (CABM001) DNA German # German 3.5 14.5 CV ES ND 3556GrC (SJ) 3556GrC (SJ)
16 9 (CABM004) Blood Scottish-Irish # Scottish-Irish 3.0 13.0 CV ES Deficient 3556GrC (SJ) 3556GrC (SJ)
17 9 (CABM009) Blood English-Irish # English-Swedish 3.3 112.0 CV Deficient 3556GrC (SJ) 3556GrC (SJ)
18 9 (CABM017) Blood English-Irish # English-German-
Irish-Indian
3.5 15.5 CV ES Deficient 3556GrC (SJ) 3556GrC (SJ)
19 5 (BD00219) LB English # English 3.0 10 CV ES; CD Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
20 5 (BD00431) LB Canadian # Canadian 2.0 18.7 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
21 3 (C7153);
5 (BD00020)
DNA
LB
English # German 2.0 7.3 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
22 3 (C9542); 5
(BD00056)
LB German # Irish-Scottish 2.0 5.8 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
23 9 (CABM0015) Blood German-Czech # Canadian-
North American Indian
3.0 14.8 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
24 10 (CABM002) DNA Danish # Danish 2.9 16.3 CV ES ND 3556GrC (SJ) 3670CrT (Arg208Stop)
25 11 (CABM003) FB northern European # northern
European
3.8 15.4 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
26 12 (CABM005) FB Scottish-English # Scottish-English 2.3 17.7 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
27 9 (CABM016) Blood Scottish-Irish-English#
Scottish-Irish-English
3.0 9.7 CV ES Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
28 2 (GUS18769) LB English-Irish-American Indian 3.0 19.0 CV ES; LMC Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
29 2 (GUS26230) LB French-Irish-German Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
30 3 (C7788) LB Irish-Scottish-English# Irish-
Scottish-English
3.0 9.7 CV ES; LMC Deficient 3556GrC (SJ) 3670CrT (Arg208Stop)
31 5 (BD00397);
13(2577)
LB
Brain
Scottish # English-Scottish 2.0 12.8 CV CD Deficient 3556GrC (SJ) 4188ArG (SJ)
32 3 (C9801) DNA French # Italian 3.0 112 CV ES ND 3556GrC (SJ) 4288-4295del
33 9 (CABM007/8)c Blood Finnish-Swedish-Norwegian
# English-Scottish-
Norwegian
3.0 16 ES ND 3556GrC (SJ) 4346GrA (Glu343Lys)
34 9 (CABM013/14)c Blood ND 3556GrC (SJ) 4655GrA (Cys365Tyr)
35 13 (1932) Brain Deficient 3556GrC (SJ) 5271GrC (Gln422His)
36 10 (CABM010) DNA Danish # Danish 2.8 14.3 CV ES Deficient 3556GrC (SJ) 5271GrC (Gln422His)
37 3 (KEW2);
5 (BD00190)
Brain
LB
French-German-Irish-Scottish-
English
7.0 30.0 CV; FP CD; LMC Deficient 3556GrC (SJ) 5457GrA (Arg447His)
38 3 (F624/C6824) DNA Czech-Ukranian # Welsh 3.0 9.5 CV; FP ES ND 3556GrC (SJ) 5541CrT (Ser475Leu)
39 5 (BD00134) LB English 2.5 8.3 CV ES; CD Deficient 3670CrT (Arg208Stop) 3670CrT (Arg208Stop)
40 5 (BD00463) LB Polish # Polish-Swedish-
French-Bohemian
2.9 7.7 CV ES Deficient 3670CrT (Arg208Stop) 3670CrT (Arg208Stop)
41 3 (C7149);
5 (BD00047)
DNA
LB
Polish-German # Norwegian-
German
3.0 113.4 CV ES ND 3670CrT (Arg208Stop) 3670CrT (Arg208Stop)
42 3 (C8149) DNA Polish # Polish 3.0 12 CV; FP ES; LMC ND 3670CrT (Arg208Stop) 3670CrT (Arg208Stop)
43 9 (CABM012) Blood Norwegian-German-Polish 3.0 15.5 ES Deficient 3670CrT (Arg208Stop) 3670CrT (Arg208Stop)
44 3 (C11496) DNA Italian # Italian 2.0 18.0 CV CD ND 3670CrT (Arg208Stop) 4396TrG (SJ)
45 5 (BD00385) LB English-German #Hungarian-
Polish-Russian
3.0 11.8 CV; FP ES Deficient 3670CrT (Arg208Stop) 5159TrA (Val385Asp)
46 5 (BD00271) LB Polish # German 3.0 6.3 CV CD Deficient 3670CrT (Arg208Stop) 5271GrC (Gln422His)
47 3 (C11571) DNA Mexican # Mexican 3.0 18.5 CV ES ND 3670CrT (Arg208Stop) 5271GrC (Gln422His)
48 3 (KEW3) Brain English-Irish 2.5 6 CV ES Deficient 3670CrT (Arg208Stop) 5271GrC (Gln422His)
49 14 (ANS1) Brain German-Irish-Polish-English 8.0 43 CV; FP Deficient 3670CrT (Arg208Stop) 5457GrA (Arg447His)
50 2 (GUS26252) LB Deficient 3670CrT (Arg208Stop) 6025GrC (SJ)
51 15 (GM09404) FB Deficient 4023TrA (Ile287Asn) Not identified
52 1 (IGF056/87) FB Italian # Italian 3.0 CV ES Deficient 4288-4295del 4288-4295del
53 2 (GUS23717) LB English #English 3.5 17.3 CV ES Deficient 4346GrA (Glu343Lys) 4346GrA (Glu343Lys)
54 16 (WG308) FB Deficient 4654TrC (Cys365Arg) 6069InsA
55 16 (WG305) FB Deficient 4655GrA (Cys365Tyr) 4655GrA (Cys365Tyr)
56 7 (DNP2) Brain Deficient 4655GrA (Cys365Tyr) 5478CrA (Ala454Glu)
57 3 (C9538);
5 (BD00013)
DNA
LB
Spanish # Spanish 2.5 10.3 CV ES Deficient 5271GrC (Gln422His) 5271GrC (Gln422His)
58 5 (BD00284) LB Romanian-Canadian#
Romanian-Canadian
3.0 8 CV VD; CD Deficient 6151-6152delTC 6151-6152delTC
59 3 (KEW4) Brain Hispanic 0.8 8 CV; G ES; CD Deficient Not identified Not identified
60 2 (GUS16766) LB Middle Eastern Deficient Not identified Not identified
NOTE.—LB  lymphoblasts; FB  fibroblasts; ES  epileptic seizures; VD  vision deterioration; CD  cognitive dysfunction; LMC  loss of motor coordination; CV  curvilinear bodies; FP 
fingerprint bodies; SJ  splice-junction mutations; G  granular osmiophilic deposits; and nd  not determined.
a Sources: 1 Instituto Gaslini; 2  T. J. Lerner; 3  Institute for Basic Research, Staten Island; 4 S. Goldwurm; 5  Batten Disease Lymphocyte Cell Bank at the University of Indiana School of
Medicine; 6  F. Hisama; 7  D. N. Palmer; 8  P. Krebs; 9  families; 10  P. Uldall; 11  E. Berry-Krais; 12 C. Greenberg and L. Dilling; 13  National Neurological Research Specimen Bank; 14 
A. N. Siakotos; 15  Coriell Cell Collection; and 16  McGill University Repository.
b Deficient CLN2 protease activities in LINCL cases ranged from 0% to 10% of normal control values, depending on sample source.
c The genotype of these patients with LINCL was inferred from sequence analysis of their respective parents.
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601780) has not been identified but has been mapped
to 15q21-23 by linkage analysis (Sharp et al. 1997;
Haines et al. 1998). In addition, progressive epilepsy
with mental retardation, or “northern epilepsy” (EPMR;
MIM 600143), should probably be considered a form
of NCL (Ranta et al. 1996).
In conjunction with genetic analysis and evaluation of
clinical progression, examination of subcellular inclu-
sion bodies by electron microscopy (EM) can help dif-
ferentiate between the different forms of NCL. INCL is
characterized by the presence of granular osmiophilic
deposits, whereas inclusion bodies of patients with clas-
sic LINCL and JNCL have a curvilinear or fingerprint
morphology, respectively. Inclusion bodies within cells
of patients with variant (CLN6) LINCL tend to have a
mixed curvilinear/fingerprint profile.
The CLN2 gene product—which is defective or miss-
ing in LINCL—was recently identified by means of an
integrated biochemical genomic strategy (Sleat et al.
1997) rather than by traditional genetic methods. The
deduced amino acid sequence from the cDNA sequence
(GenBank accession number AF017456) of this previ-
ously unidentified protein revealed significant similarities
with pepstatin-insensitive proteases from Xanthomonas
and Pseudomonas, suggesting a similar catalytic func-
tion. This was confirmed when a pepstatin-insensitive
protease activity was found to be missing in LINCL sam-
ples that were compared with normal controls. Recently,
tripeptidyl peptidase I (TPPI) activity was found to be
missing in LINCL fibroblasts (Vines and Warburton,
1999). This observation and a comparison of the murine
TPPI and CLN2 protease sequences (GenBank accession
numbers AJ011912 and AF111172, respectively) sug-
gest that TPPI is the same as the CLN2 protease. It is
not clear how the loss of this protease results in LINCL,
but it does result in the accumulation of mitochondrial
ATPase subunit c (Palmer et al. 1992). Whether this is
a direct or an indirect consequence of CLN2 protease
deficiency, and whether subunit c accumulation contrib-
utes directly to neuronal cell death, are questions that
remain to be answered. LINCL is unusual among the
lysosomal storage diseases in that it results from a de-
ficiency in an acid protease activity. The other reported
example is cathepsin K deficiency in pycnodysostosis
(Gelb et al. 1996), which, unlike LINCL, is not neurod-
egenerative in nature.
A limited preliminary molecular analysis revealed four
CLN2 mutations associated with LINCL: a splice-junc-
tion mutation, a nonsense mutation, and two different
missense mutations in the same codon (Sleat et al. 1997).
The complete sequence of CLN2 was subsequently de-
termined (GenBank accession number AF039704; Liu et
al. 1998), facilitating the design of a set of primers for
the generation of overlapping PCR products spanning
the entire coding sequence, the 5′ untranslated sequence
(UTS), part of the 3′ UTS, most of the intronic sequence,
and part of the 5′ untranscribed sequence, which pre-
sumably contains promoter elements. In the current
study, our aim was to conduct a definitive genetic anal-
ysis of CLN2, using these primer sets, in a large pop-
ulation of patients with LINCL, to characterize the spec-
trum of molecular defects. We expected to shed light on
the molecular pathology of LINCL and to aid in the
development of an effective molecular genetic strategy
for diagnosis and carrier testing. We identify 24 different
CLN2 mutations in patients with LINCL, of which 20
have not been previously described. One missense mu-
tation, which presumably does not result in complete
functional inactivation of the CLN2 protease, was as-
sociated with a late-onset and protracted form of LINCL
in two families previously diagnosed with JNCL.
Patients and Methods
Patients
This study group encompasses 74 families with pa-
tients whowere diagnosed with LINCL by classic clinical
criteria (age at onset, clinical progression, and, when
available, ultrastructural pathology [Kohlschutter et al.
1993]). Two other families represented patients origi-
nally diagnosed with JNCL. One (ANS1) was identified
in the course of screening brain autopsy specimens for
lysosomal enzyme deficiencies by means of mannose 6-
phosphate glycoprotein blotting methods described else-
where (Sleat et al. 1996; Valenzano et al. 1993). The
other (KEW2/BD00190) was a patient with JNCL-like
clinical progression but with no detectable mutations in
CLN3 and with a mixed fingerprint/curvilinear inclusion
morphology (Wisniewski et al. 1998b). Samples were
obtained from cell and tissue banks, including the Batten
Disease Support and Research Association and the Chil-
dren’s Brain Foundation Batten’s Disease Lymphocyte
Cell Bank (Indiana University School of Medicine), the
Batten Disease Registry (Institute for Basic Research,
Staten Island), Massachusetts General Hospital, the Is-
tituto Giannina Gaslini (Genova, Italy), the National
Neurological Research Specimen Bank (West Los An-
geles Veterans Administration Medical Center), the Mi-
ami Brain Bank, the McGill University Cell Repository,
and the Corriell Cell Collection (Camden, New Jersey).
These samples can be accessed from their respective col-
lections with the identification codes listed in the present
study. Other samples were obtained from physicians and
families directly, according to an institutional review
board–approved protocol, and are prefixed with Center
for Advanced Biotechnology codes. All samples and their
respective sources are listed in table 1.
DNA samples were not available from two patients
with LINCL. In these cases (which are noted in table 1),
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Table 2
Patients Diagnosed with LINCL Who Are Not CLN2 Protease Deficient
Family
Source
(Identifier)a
Sample
Type
Age at
Onset
(years)
Lifespan
(years) EM
CLN2
Protease
PCR Products
Sequenced
61 4 (BD00357) LB 2.0 17.7 CV; FP Not deficient A–I
62 4 (BD00043) LB 4.0 17.5 CV; FP Not deficient D–H
63 4 (BD00388) LB 4.0 114.8 CV; FP Not deficient D–H
64 3 (C7097) LB 2.5 8.5 CV Not deficient A–M
65 2 (GUS23572) LB 3.5 111.0 CV; FP; G Not deficient H
66 4 (BD00499) LB 2.5 18.0 CV; FP; G Not deficient None
67 3 (C6958) FB 2.5 8.0 CV; FP Not deficient None
68 4 (BD00501) LB 2 14.0 CV Not deficient A–M
69 1 (IGF075/86) FB Not deficient A–M
70 1 (IGF117/85) FB Not deficient A–M
71 1 (IGF026/90) FB Not deficient A–M
72 1 (IGF078/84) FB Not deficient A–M
73 3 (C10789) FB 2 17.0 CV; FP Not deficient A–M
74 3 (C7464) LB 2 10.0 CV; FP Not deficient A–M
NOTE.—LB  lymphoblasts; FB  fibroblasts; CV  curvilinear bodies; FP  fingerprint bodies; and G
 granular osmiophilic bodies.
a Sources: 1 Instituto Gaslini; 2  T. J. Lerner; 3  Institute for Basic Research, Staten Island; and 4
 Batten Disease Lymphocyte Cell Bank at the University of Indiana School of Medicine
the mutant alleles associated with LINCL were inferred
from sequence analysis of the parents.
We analyzed 60 families with classic LINCL. CLN2
was also completely or partially sequenced in 8 normal
individuals and in 19 patients affected with diseases
other than LINCL.
Preparation of Genomic DNA
Primary human fibroblasts and transformed lympho-
blasts were cultured in Roswell Park Memorial Institute
media containing 10% or 15% heat-inactivated fetal
bovine sera, respectively, with penicillin-streptomycin
and nystatin (Gibco BRL). We prepared patient DNA
from human brain autopsy samples (50 mg), cultured
cells (∼107 cells), or whole blood (200 ml) collected in
the presence of citrate, using either the QiaAmp Tissue
DNA purification kit (Qiagen Inc.) or standard phenol-
extraction protocols. Genomic DNA was stored at
20C, in water.
Sequence Analysis of CLN2
Mutational analysis of patients with LINCL was
achieved with 13 PCR primer pairs, designated A–M
(fig. 2), that allow amplification of the entireCLN2 cod-
ing sequence, all of the intron-exon splice junctions,
most of the intervening intronic sequence, and ∼300 bp
of the 5′ untranscribed sequence (Liu et al. 1998). In
cases for which brain autopsy material, blood samples,
or cell lines were available, we initially confirmed the
diagnosis of LINCL by using the clinical CLN2 protease
assay developed in our laboratory (Sohar et al., in press).
Patients that lacked CLN2 protease activity were sub-
jected to genetic analysis, until both of the mutant alleles
were identified or all 13 amplification products were
sequenced. The CLN2 gene of most patients initially
diagnosed with LINCL, but who were not CLN2 pro-
tease deficient, was subjected to a limited sequence anal-
ysis focusing on the two common mutant alleles that
together comprise approximately two-thirds of all mu-
tant alleles in LINCL (table 2). This was done to confirm
that these samples did not represent false positives in
the enzyme assay. Eleven samples were obtained only as
DNA. These were subjected to genetic analysis, until
either both of the mutant alleles were identified or all
13 amplification products were sequenced. In two of
these cases, no mutations were identified after use of all
13 PCR primer sets, which suggests that these patients
suffered from disorders other than LINCL. However, the
possibility that pathogenic alleles are present, in regions
of the gene excluded from our sequence strategy, cannot
be discounted.
To allow dye-labeled primer-cycle sequencing, the for-
ward primers contained the complement to the21M13
primer, and the reverse primers contained the comple-
ment to the M13 reverse primer. PCR products were
generated by use of 2 U AmpliTaq Gold (Perkin-Elmer)
in 100-ml reactions comprising 200 ng genomic DNA,
0.2 mM of each deoxynucleotide, 200 pmol of each
primer, 2 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl
(pH 8.3), and 0.001% (w/v) gelatin. PCR cycling con-
ditions were as follows: 94C for 11 min, for polymerase
activation and DNA denaturation; 10 cycles of 94C for
1 min, 55C for 1 min, and 72C for 1 min; 30 cycles
of 94C for 1 min, 68C for 1 min, and 72C for 1 min;
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followed by 72C for 10 min, and then 4C until prod-
ucts were purified. Amplified products were purified by
use of QiaQuick PCR purification spin columns (Qia-
gen), eluted in 50 ml water at 25–100 ng/ml, and se-
quenced by ABI PRISM Dye Primer Cycle Sequencing
kits (Perkin-Elmer) and an ABI 373 automated se-
quencer. The resulting sequence files were edited by FAC-
TURA and assembled by AUTOASSEMBLER (Applied
Biosystems).
We initially detected candidate mutations in CLN2 by
sequencing using the M13-21 dye-labeled primer, except
for amplified products from exon 8, which we sequenced
using the M13 reverse primer. After the first sequence
analysis, we clarified regions of ambiguity, if present, by
sequencing the opposite strand. PCR reactions yielding
products containing potential mutations were then re-
peated, and the resulting products were resequenced on
the strand opposite that sequenced initially—or, in most
cases, in both directions—to verify the mutation.
Results
Identification of CLN2 Homologues
The first indication that the protein encoded byCLN2
was related to a group of unusual bacterial pepstatin-
insensitive proteases came from database searches,
which revealed significant sequence similarity with pro-
teases from Xanthomonas and Pseudomonas (GenBank
accession numbers D83740 and D37970). In the present
study, we conducted a further database search for other
proteins with similarity to the CLN2 protease, to identify
regions that are likely to be of structural or functional
importance, thus aiding interpretation of CLN2 muta-
tions in LINCL. In addition to the two bacterial pro-
teases, four other less but significantly ( ) similarP ! .001
potential CLN2 homologues have been identified. These
are a Dictyostelium discoideum vegetative stage–specific
V4-7 mRNA (GenBank accession number U27540), a
gene encoded within a 100-bp fragment of the Sulfo-
lobus solfataricus genome (GenBank accession number
Y08256), the Physarum polycephalum PHP gene
(GenBank accession number X64708), and an Epichloe
typhina protease gene (GenBank accession number
L76740). The murine CLN2 protease (GenBank acces-
sion number AF111172; also listed as murine TPPI [ac-
cession number AJ011912]) has also been included in
the sequence alignment presented in figure 1. It is clear
that there are scattered regions of similarity throughout
these proteins, but there are three blocks of high simi-
larity, corresponding to amino acids Ala347–Gly362
(box 1), Pro379–Thr391 (box 2), and Gly473–Gly483
(box 3) of CLN2, which suggests that these regions may
be of functional importance.
CLN2 Protease Activities in Patients with LINCL
In a parallel study, we have developed a rapid and
sensitive assay for the CLN2 protease that is applicable
to a wide range of clinical samples, including blood,
fibroblasts, lymphoblasts, and brain autopsy material
(Sohar et al. 1999). Throughout the present study, we
have, when possible, used this assay for biochemical di-
agnosis of LINCL, limiting extensive sequence analysis
only to samples that are CLN2 protease deficient (table
1). In validating the diagnostic CLN2 protease assay, we
conducted limited sequence analysis on most samples
that were not CLN2 protease deficient, using the H
primer set that detects the presence of one or more mu-
tant alleles in ∼80% of patients with LINCL (table 2),
and in six cases we analyzed the entire CLN2 coding
sequence. No mutations were identified in any patients
who were not CLN2 protease deficient.
Forty-seven cell lines were obtained from patients di-
agnosed with LINCL. Fourteen of these were found to
contain CLN2 protease activity and thus probably rep-
resent other NCLs (table 2). It is noteworthy that, where
morphological or ultrastructural data were available,
only 4 of the 35 genetically confirmed cases with LINCL
had mixed curvilinear and fingerprint inclusions rather
than the typically observed curvilinear bodies alone,
whereas 8 of 10 patients who were not CLN2 protease
deficient had mixed inclusions. A mixed storage-body
morphology is typical of variant LINCL (Sharp et al.
1997), suggesting that, in some of these patients, disease
may result from defects in CLN6.
Both mutant alleles were identified in all patients who
lacked CLN2 protease activity, with the exception of
three. In one case, CLN2 protease was measured in a
frozen brain autopsy sample (KEW4), and it is possible
that extrinsic factors involved in the removal or storage
of the tissue may have resulted in a loss of activity. This
is not the case with another patient, in whom no mu-
tations were identified and yet whose lymphoblasts
(GUS16776) lacked CLN2 protease activity. In another
patient, represented by cell line GM09404, only one
pathogenic allele could be found. It is possible that, in
all three patients, pathogenic alleles lie outside the scope
of our sequence analysis (i.e., 1300 nucleotides upstream
of the transcription start site, within intron 3, or within
the 3′ UTS). Another possibility is that mutations in an-
other protein, perhaps required for the stability or pro-
cessing of the CLN2 protease, result in LINCL. A prec-
edent for this already exists for the lysosomal storage
disease galactosialidosis (D’Azzo et al. 1982). In this
disease, mutations within lysosomal protective protein
(cathepsin A) result in a combined b-galactosidase and
a-neuraminidase deficiency.
Figure 1 Sequence alignment of the human CLN2 protease, with eukaryotic and prokaryotic homologues. CLN2 protease homologues
were identified by use of the program TBLASTN 2.0.6 (Sept-16-1998) to search the GenBankNon-Redundant database. Sequenceswith significant
( ) sequence similarity to the CLN2 protease were aligned by use of the GCG program PILEUP, with ENDWEIGHT (Genetics ComputerP ! .001
Group 1991), and compiled for publication by use of BOXSHADE 3.21 (ISREC Bioinformatics Group [Swiss Institute for Experimental Cancer
Research]). Regions of homology (boxes 1–3) are underlined.
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Table 3
Frequency of CLN2 Polymorphisms in an Unrelated Population Sample
NUCLEOTIDE POSITION
SAMPLES
ANALYZED
ALLELE
PERCENTAGE OF
GENOTYPE
1 2 1a/1 1/2 2/2
1089 5′ untranscribed 46 T C 54.4 30.4 15.2
1177 5′ untranscribed 47 G A 91.5 2.2 6.4
1205 5′ untranscribed 46 T C 89.1 4.4 6.5
1224 5′ untranscribed 45 G A 97.8 2.2 .0
1767 Intron 2 58 C T 98.3 1.7 .0
3004 Exon 4 56 A G 89.2 5.4 5.4
3436 Intron 5 67 A T 46.3 40.3 13.5
3767 Intron 6 126 T C 62.7 30.2 7.1
5044 Intron 9 64 C G 86.0 14.0 .0
5276 Intron 10 82 G A 97.6 .0 2.4
5837 Exon 12 63 A T 84.1 14.3 1.6
5644 Intron 11 43 T C 72.0 23.3 4.7
5658 Intron 11 42 A G 95.2 4.8 .0
a The relative frequency of each polymorphism was calculated from a large number
of patients with LINCL and their immediate families, patients with unrelated dis-
orders, and normal controls. To avoid redundancy, results from only one affected
sibling are included here. In families in which the parents have been analyzed these
data are included in place of data of the respective proband, to increase the scope
of the survey among unrelated individuals.
Table 4
Summary of CLN2 Mutations that Do Not Involve Intron-Exon
Splice Junctions
Nucleotide Change
Mutation
Type Location
Amino Acid
Change
No. of
Alleles
(%)
1917CrT Nonsense Exon 3 Gln66Stop 2 (1.7)
1950GrA Missense Exon 3 Gly77Arg 1 (.9)
3081-3091del Deletion Exon 4 Frameshift 2 (1.7)
3084CrT Nonsense Exon 4 Arg127Stop 1 (.9)
3670CrT Nonsense Exon 6 Arg208Stop 32 (27.8)
4023TrA Missense Exon 7 Ile287Asn 1 (.9)
4288-4295del Deletion Exon 8 Frameshift 3 (2.6)
4346GrA Missense Exon 8 Glu343Lys 3 (2.6)
4654TrC Missense Exon 9 Cys365Arg 1 (.9)
4655GrA Missense Exon 9 Cys365Tyr 4 (3.5)
5159TrA Missense Exon 10 Val385Asp 1 (.9)
5171GrAa Missense Exon 10 Gly389Glu 4 (3.5)
5271GrC Missense Exon 10 Gln422His 8 (7.0)
5457GrA Missense Exon 11 Arg447His 2 (1.7)
5478CrA Missense Exon 11 Ala454Glu 1 (.9)
5541CrT Missense Exon 11 Ser475Leu 1 (.9)
6069InsA Insertion Exon 13 Frameshift 1 (.9)
6151-6152delTC Deletion Exon 13 Frameshift 2 (1.7)
a This missense mutation was always found in association with
A3004G (Gln100Arg), which is listed as a probable polymorphism in
table 3 (for reasons, see Results).
CLN2 Polymorphisms
We identified 13 CLN2 polymorphisms in the se-
quence analysis of the 60 LINCL families, 8 normal
controls, and 19 patients with other genetic diseases.
These polymorphisms are listed in table 3. Most were
located in the 5′ untranscribed sequence or within in-
trons, but two silent polymorphisms were identified
within coding regions.
CLN2 Mutations
In the present study, we have identified the CLN2
defects associated with disease in 58 LINCL families.
Samples from these patients, their respective sources, and
repository access numbers are listed in table 1. Twenty-
four mutations were identified, 20 of which are previ-
ously unreported (table 1). These mutations, their pre-
dicted effects on the CLN2 gene product, and their fre-
quency of incidence are summarized in tables 1, 4, and
5, and their respective locations within CLN2 are in-
dicated in figure 2. In 21 of the 58 families, the CLN2
gene contained homozygous changes, and the remaining
37 were compound heterozygous. Half (12 of 24) of the
different mutations were identified in only a single pa-
tient (private mutations), whereas two mutations were
particularly common (3670CrT and 3556GrC) and ac-
counted for 60% of all CLN2 mutant alleles.
Eleven CLN2 missense mutations were identified
within the LINCL families (table 4) but not in the
healthy controls or patients affected with other genetic
diseases. Most of the missense mutations do not result
in amino acid substitutions at highly conserved residues
except Val385 and Gly389, which are highly conserved
or invariant components of box 1, between the CLN2
protease and its homologues (fig. 1 box 1).
Two different LINCL patients of Romany ethnicity
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Table 5
Summary of CLN2 Splice-Junction Mutations
NUCLEOTIDE
CHANGE LOCATION
MUTATION
CLASSa
NO. OF
ALLELES
(%)
SPLICE-SITE CONSENSUS SEQUENCEb
5′ (Donor):
NMAGGTRAGTN NMAGGTRAGTN
3′ (Acceptor):
YYNYAGRNNNN YYNYAGRNNNN
1946ArG Exon 3 1 1 (.9) CTCAATACGGTrCTCAGTACGGT
4396TrG Intron 8 2 1 (.9) TCAGGTGACCTrTCAGGGGACCT
3556GrA Intron 5 2 3 (2.6) CTACAGTGGGGrCTACAATGGGG
3556GrC Intron 5 2 38 (33.0) CTACAGTGGGGrCTACACTGGGG
4188ArG Intron 7 1 1 (.9) AAAAAAAAAAArAAAAAGAAAAA
6025GrC Intron 12 2 1 (.9) CCCTAGGTAACrCCCTACGTAAC
a Mutation classes represent (1) generation of a cryptic splice junction and (2) changes in invariant splice-junction residues.
b Exonic sequences are in italics; underlined residues are invariant. Codes are M  A or C, R  A or G, N  any base, and Y  C or T.
were found to be homozygous for two missense muta-
tions that were not observed in any other patients with
LINCL (5171GrA [Gly389Glu] and 3007GrA
[Gln100Arg]). It is probable that one of these changes
represents a true mutation and the other a closely linked
polymorphism. If this is the case, then Gly389Glu is the
more likely candidate for a pathogenic allele, because
this is a completely conserved residue (fig. 1, box 1).
Another possibility is that each of these changes alone
is not sufficient to result in an inactive CLN2 protease
but their compound effect is. Familial genetic analysis
does not shed light on this question, as both parents of
one patient were heterozygous for both of the changes.
Future structure-function analyses of the CLN2 protease
should resolve this issue.
A number of mutations were observed within the in-
variant intronic elements of splice junctions, including
3556GrC, which accounts for ∼32% of all LINCL mu-
tant alleles. Two nucleotide changes were also identified,
which potentially create cryptic splice junctions in close
proximity to known sites. In one, 1946GrA, which is
within exon 3, a potential splice site is generated that is
just upstream of an established splice-donor site. Pre-
mRNA processing at this cryptic site would result in a
five-nucleotide deletion in the mature mRNA and a sub-
sequent frameshift. Splicing at another cryptic site, re-
sulting from mutation 4188ArG, would also cause a
frameshift by adding 17 nucleotides to the final mRNA.
In this case, the cryptic splice junction is in a more fa-
vorable context for splicing than the original because it
is preceded by a TC-rich sequence, whereas the original
is preceded by a run of 19 A residues, which is unusual
and not generally considered typical of a splice junction.
Neither of these cryptic splice sites has been proved by
experiment; the possibility remains that they are poly-
morphisms and that the true mutations are yet to be
identified. However, it should be noted that neither of
these nucleotide changes was found in any of the normal
controls or in any of the patients with LINCL, in whom
both mutant alleles had been definitively identified, and
where genetic analyses included the regions containing
these two potential mutations (42 samples for nucleotide
1946, and 45 samples for nucleotide 4188).
Three nonsense mutations were identified, including
3670CrT (Arg208Stop), which accounted for ∼28% of
the mutant alleles. In addition, four frameshifts resulting
from small deletions or insertions were also found, in-
cluding a 2-nucleotide deletion located only 13 nucle-
otides upstream from the TGA stop codon. This frame-
shift mutation changes the four carboxy-terminal amino
acids of CLN2 and is predicted to add 13 amino acids.
Two of the mutant alleles identified by Sleat et al.
(1997) (3556GrC and 3670CrT) account for 60% of
all CLN2 mutations detected in the present study. Both
of these alleles were found in 40% of patients (genotypes
3556[C/C]:3670[C/C], 3556[G/C]:3670[C/T], or
3556[G/G]:3670[T/T]), whereas 38% of patients con-
tained one of these two alleles (genotypes 3556[G/C]:
3670[C/C] or 3556[G/G]:3670[C/T]); thus, a total of
78% of patients with LINCL contain one or two of these
al le les . The other mutations (Cys365Arg and
Cys365Tyr) identified by Sleat et al. (1997) were not
commonly found in patients with LINCL, representing
together only 4.2% of all mutant alleles.
Clinical Parameters and CLN2 Mutations
One of the aims of the present study was to determine
whether the clinical progression of LINCL could be pre-
dicted from the CLN2 genotype. However, it is clear
from table 1 that, with the exception of two patients
(ANS1 and BD00190), the clinical progression of
LINCL in our study population was relatively homo-
geneous and thus uninfluenced by the type of mutation
involved.
Patients ANS1 and BD00190 represent two appar-
ently unrelated individuals who were originally diag-
nosed with JNCL, both with onset at age ∼8 years and
death at ages 43 years and 30 years, respectively. Both
of these patients are compound heterozygous. Patient
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Figure 2 Schematic drawing of the CLN2 gene, showing the positions of mutations associated with LINCL. Deletions, insertions, nonsense,
and missense mutations are indicated above the schematic, and mutations involved in splicing are indicated below.
ANS1 is heterozygous for the common Arg208Stop mu-
tation (3670C/T), and patient BD00190 is heterozygous
for the common splice-junction mutation (3556G/C),
but both share a unique monoallelic CLN2 mutation
that is not observed in the other patients with LINCL.
This mutation (5457GrA) results in a missense muta-
tion, Arg447His. A limited familial analysis of these pa-
tients indicated that the Arg447His mutation is associ-
ated with protracted LINCL. In the case of patient
ANS1, one parent of the proband was heterozygous for
the Arg208Stop mutation (3670[C/T]:5457[G/G]),
whereas the other parent was heterozygous for the
Arg447His change (3670[C/C]:5457[G/A]). An unaf-
fected sibling carrier was identical to the first parent at
these alleles, being heterozygous for only the
Arg208Stop mutation. In the case of patient BD00190,
an affected sibling (BD00196) was genotypically iden-
tical (3556[G/C]:5457[G/A]) to the proband. Clinical
progression of the typical and atypical LINCL cases,
including two affected siblings of patient BD00190, is
summarized in table 6.
When analyzing our study population with respect to
mutation incidence, we also considered the ethnic origin/
race of the patients, when known. Incidence of LINCL
was panethnic, but a disproportionate number (24/50)
of patients were completely or largely of English-Scot-
tish-Irish extraction. There was little correspondence be-
tween the types of mutation and ethnic background,
although the two common mutations (3670CrT and
3556GrC) were identified more frequently in patients
of predominantly northern European origin. For ex-
ample, pathogenic alleles in 58% of patients of predom-
inantly northern European origin are restricted to the
two commonmutations, comparedwith 24%of patients
of eastern, central, or southern European origin. Ethnic
linkage was observed with two mutations. A double ho-
mozygous missense mutation (Gln100Arg:Gly389Glu)
was identified only in two patients of Romany origin
residing in Italy. In addition, a homozygous deletion
(4288-4295del) was identified in a patient of Italian de-
scent and was also one of the pathogenic alleles in a
compound-heterozygous genotype, in a patient of mixed
Italian-French descent.
Discussion
In the present study, we have located pathogenic
CLN2 alleles in 58 patients with LINCL, identifying 24
mutations, 20 of which were previously undescribed.
Two CLN2 mutations that were originally identified in
LINCL—a splice-junction mutation and a nonsense mu-
tation—were found to be particularly common, together
accounting for 60% of mutant alleles (an observation
made also by Zhong et al. 1998). At least one of either
of these two common mutations is detected in 78% of
all patients with LINCL, and both are amplified on the
same exon 6 fragment with the H primer set (Liu et al.
1998), indicating that molecular genetic diagnosis of
LINCL should be a practical proposition. However, the
rest of the observed LINCL mutations, which each in-
dividually account for ∼1%–7% of the total number of
observed mutant alleles, are scattered throughout the
CLN2 coding sequence. In the absence of clues from
ethnicity (see Results), these alleles are potentially dif-
ficult and time consuming to identify. Therefore, a se-
quential sequencing strategy is presented here, which al-
lows for the most rapid identification of mutant alleles,
with the smallest number of PCR/sequencing reactions.
In this optimized strategy, the sequential order of exon
sequencing is dictated by a function of both the relative
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Figure 3 An optimized sequencing strategy for efficient identi-
fication of CLN2 mutations associated with LINCL.
Table 6
Clinical Synopsis of Typical and Atypical Cases of Classic LINCL
Classic LINCL Subtype
Age at
Onset
(years)
Lifespan
(years)
Late-onset, protracted LINCL:
Family 50 (ANS1) 8 43
Family 39 (BD00190 and 2 affected siblings)a 6–8 24, 30, 129
Overall 7.3.5 131.58.1
Typical LINCL 2.90.4b 18.32.8c
a BD00190, BD00196, and BD00190sib represent three affected siblings, the
latter of which was not included in this study. ANS1 is unrelated.
b ; range 2.0–3.8.n  46
c ; range 3.0–16.0.n  43
frequency of each mutation contained within each exon
and the number of different mutations contained within
each exon. The value of this approach in the identifi-
cation of mutant alleles, as a percentage of total and for
identification of both mutant alleles in patients with
LINCL, is demonstrated in figure 3. The probability of
identifying at least one mutant allele as the exons are
sequentially analyzed is also presented, as this may be
sufficient for the initial diagnosis. (The efficiency of di-
agnosis, defined by the detection of at least one mutant
allele, can be improved slightly by altering the order of
sequencing to PCR products H, D, F, E, A, G, C, and J
[data not shown]). Additional sequencing may be re-
quired for patients in whom both alleles are not iden-
tified (e.g., patients KEW4, GUS16776, and GM09404).
Little is currently known about the synthesis or pro-
cessing of the CLN2 protease, other than that the pri-
mary translation product contains an ∼25–kD light
chain or propiece preceding the N-terminus of the 46-
kD form that was originally purified (Sleat et al. 1997).
In this study, 10 of 11 missense mutations identifiedwere
located within the 46-kD C-terminal portion of the pre-
dicted protein. This clustering of missense mutations
suggests that the 25-kD N-terminal portion of the pri-
mary translation product actually represents a propiece
that is not required for the catalytic function of the
CLN2 gene. This is typical of lysosomal proteases,which
are synthesized as zymogens and activated within acid-
ified compartments by removal of propieces (reviewed
by Gabel 1993).
Two unrelated patients (ANS1 and BD00190) were
originally diagnosed with JNCL on the basis of age at
onset, age at death, and inclusion morphology. EM anal-
ysis of a postmortem brain sample from one patient
(ANS1) was reported to have found fingerprint inclu-
sions, which are typical of JNCL, although analysis of
buffy-coat leukocytes revealed both curvilinear and fin-
gerprint profiles. EM analysis of buffy-coat leukocytes
from patient BD00190 and siblings also revealed a
mixed inclusion morphology. We analyzed CLN2 pro-
tease activities in samples (brain autopsy samples and/
or cell lines) derived from these patients, as potential
atypical LINCL cases, and confirmed a lack of activity.
Sequence analysis determined that the CLN2 defects in
both probands and an affected sibling of one were com-
pound heterozygous, with either monoallelic common
splice-junction or Arg208Stop mutations. However,
both of these atypical patients shared a rare monoallelic
mutation that resulted in the substitution of arginine 447
for histidine, which was not observed in other patients
with LINCL. It is likely that this mutation causes an
incomplete loss of function of the CLN2 protease, re-
sulting in the protracted phenotype. CLN2 protease ac-
tivity was not detectable in samples from these patients,
suggesting that any residual activity was very low com-
pared with normal controls. Such observations are not
uncommon with other lysosomal storage diseases, in
which missense mutations result in a partial dysfunction
and subsequent mild or protracted phenotype (reviewed
by Gieselmann 1995).
The Arg447His mutation appears to be rare, on the
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basis of the results of this study, but it should be kept
in mind that we analyzed, for the most part, only pa-
tients diagnosed with LINCL, expressing typical clinical
progression. Thus one intriguing possibility is that there
may exist individuals who are homozygous for
Arg447His. The likely phenotype of such an individual
remains open to speculation. It is possible that homo-
zygosity for Arg447His may have no apparent patho-
genic effects or, alternatively, that this genotype could
result in a highly attenuated form of LINCL that might
not be diagnosed or that might be confused with other
late-onset neurodegenerative disorders. CLN2 defects do
not, however, appear to be responsible for adult NCL
(Kufs disease), as CLN2 protease activities are the same
or higher than controls in adult NCL lymphoblasts (So-
har et al. 1999).
With the identification of the defective genes in the
three most common forms of NCL and subsequent mo-
lecular genetic analyses of atypical forms, it is becoming
increasingly apparent that there exist atypical late-onset
or protracted variants of each. In this study, we have
identified a CLN2 mutation that results in a phenotype
more characteristic of JNCL. Other recent studies high-
light CLN1 mutations that result in clinical expression
more typical of CLN2 or CLN3 defects (Das et al. 1998;
Mitchison et al. 1998; Wisniewski et al. 1998a, 1998b)
and CLN3 mutations that result in a greatly protracted
clinical course (Munroe et al. 1997). However, in con-
junction with traditional parameters (clinical history and
subcellular morphology) and rapid biochemical tests,
molecular genetic analyses of the type described here
now allow for the unequivocal diagnosis of each of type
of NCL, allowing prenatal and presymptomatic testing
in addition to heterozygote identification in affected
families. In addition, the ability to determine precisely
the defective gene in affected children may also allow
for the development of targeted therapeutic approaches
that are specifically tailored to each NCL subtype.
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